Thanks, Erin, and good morning, everyone. Now, on slide four, where I’ll cover the first quarter financial results. Sales came in at $315 million, and that's down 12% compared to last year. Pricing overall was unfavorable by about 9%, primarily due to a 12% unfavorable impact from raw material pass-through pricing following costing decreases in benzene and also propylene. Market-based pricing was unfavorable -- was favorable actually by approximately 3% compared to the prior year, reflecting improved performance in our nylon, ammonium sulfate, and caprolactam product lines, partially offsetting this was a decline in chemical intermediates pricing due to the lengthening of acetone supply globally. Volume overall was down about 3%, primarily due to the unfavorable impact of the phenol force majeure and continued challenging acetone industry dynamics, partially offset by improved nylon production. EBITDA was $42 million in the quarter, that’s ups about $11 million versus the prior year. And as a reminder, the significant weather event last year resulted in an approximately $30 million unfavorable impact to pretax income in the first quarter of 2018. And as Erin mentioned, this year's results included an $8 million unfavorable impact related to the phenol force majeure that was announced in March, including the impact of fixed cost absorption, lost sales and incremental logistics costs. In addition, we recorded a $6.6 million favorable benefit in the quarter from business interruption insurance proceeds related to the first quarter of 2018 weather event claim. Overall, we saw favorable market-based pricing offset by lower than expected operational performance and the unfavorable impact of challenging acetone industry dynamics. Earnings per share of $0.68 nearly doubled versus the prior year, driven by the factors just highlighted as well as lower interest expense and a lower share count. Our diluted share count for the first quarter of 2019 was approximately 29.8 million shares that’s a declined versus last year, driven by continued share repurchases. Share repurchases contributed to $0.04 of EPS accretion year-over-year. Partially offsetting this was an increase in our effective tax rate year-over-year, which came in close to our expectations right around 25.3% in the quarter, as well as higher depreciation and amortization expense. And lastly, cash flow from operations reached $42 million in the quarter, that's down a modest $2 million compared to last year. CapEx of $40 million was up roughly $9 million year-over-year as we continue to execute against our pipeline of high return growth and cost savings capital projects. Now, let me turn the call back over to Erin to discuss what we're seeing in each of our product lines.